No quarterly revenue total was found in Zura Bio Limited's SEC filings.
Zura Bio Limited (ZURA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$19,534.
Revenue
—
Net income
$-25.82M
-43.2% vs year-ago quarter
Operating cash flow
$-19,498
-26.2% vs year-ago quarter
Free cash flow
$-19,534
-26.2% vs year-ago quarter
EPS
$-0.20
+4.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
96.33M
+48.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855644
- Former names
- JATT Acquisition Corp (until Mar 21, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$28.8M | -$29.3M | -$25.5M | -$18.4M | -$19.5M |
| Net income | -$25.8M | -$26.3M | -$24.2M | -$17.2M | -$18.0M |
| Diluted EPS | -$0.20 | -$0.21 | -$0.22 | -$0.48 | -$0.21 |
| Operating cash flow | -$19,498 | $18.9M | -$18.9M | -$64.8M | -$15,444 |
| Free cash flow | -$19,534 | $18.9M | -$18.9M | -$64.9M | -$15,476 |
| Total assets | $194.6M | $213.4M | $228.6M | $113.9M | $143.9M |
| Total liabilities | $17.0M | $16.3M | $11.7M | $12.4M | $25.5M |
| Stockholders' equity | $177.7M | $197.1M | $216.9M | $101.5M | $109.8M |
| Cash and investments | $187.7M | $205.1M | $225.6M | $109.4M | $139.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 27, 2026 | Oct 27, 2026 |
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 17, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 1, 2026 | Jul 1, 2026 |
All 446 Zura Bio Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.